Marco Filetti

Pubblicazioni

Titolo	Pubblicato in	Anno
New driver alterations in non-small cell lung cancer: A narrative review	PRECISION CANCER MEDICINE	2022
133P ARID1A-mutated cancers: New prospectives for treatment of a subgroup of gynecological cancer	ANNALS OF ONCOLOGY	2022
1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis	ANNALS OF ONCOLOGY	2022
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)	JOURNAL OF THORACIC ONCOLOGY	2022
ACCESS TO EARLY PHASE CLINICAL TRIALS AT THE TIME OF THE COVID-19 PANDEMIC: AN ITALIAN SURVEY	ANNALS OF RESEARCH IN ONCOLOGY	2022
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index	EUROPEAN JOURNAL OF CANCER	2021
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY	2021
CT based radiomic approach on first line pembrolizumab in lung cancer	SCIENTIFIC REPORTS	2021
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study	THORACIC CANCER	2021
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation	CANCER IMMUNOLOGY, IMMUNOTHERAPY	2021
Statins and immunotherapy. Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC	CANCER REPORTS	2021
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort	JOURNAL OF TRANSLATIONAL MEDICINE	2021
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care. a national survey	SUPPORTIVE CARE IN CANCER	2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study	EUROPEAN JOURNAL OF CANCER	2021
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer	ESMO OPEN	2021
Breast cancer drug approvals issued by EMA: A review of clinical trials	CANCERS	2021
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2)	JOURNAL FOR IMMUNOTHERAPY OF CANCER	2021
Comprehensive genomic profiling in large cell neuroendocrine lung cancer: The times they are a-changin'	RECENTI PROGRESSI IN MEDICINA	2021
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study	JAMA ONCOLOGY	2021

Pubblicazioni

Progetti di Ricerca